Clal Biotechnology Industries Ltd. 13D and 13G filings for Elicio Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-04-10 4:01 pm Sale | 2024-04-08 | 13D | Elicio Therapeutics, Inc. ELTX | Clal Biotechnology Industries Ltd. | 481,727 4.680% | -117,470 (-19.60%) | Filing |
| 2024-03-20 9:07 pm Sale | 2024-03-18 | 13D | Elicio Therapeutics, Inc. ELTX | Clal Biotechnology Industries Ltd. | 599,197 5.830% | -90,372 (-13.11%) | Filing |
| 2023-12-27 4:07 pm Unchanged | 2023-12-22 | 13D | Elicio Therapeutics, Inc. ELTX | Clal Biotechnology Industries Ltd. | 689,569 7.120% | 0 (Unchanged) | Filing |
| 2023-08-30 5:16 pm Unchanged | 2023-08-28 | 13D | Elicio Therapeutics, Inc. ELTX | Clal Biotechnology Industries Ltd. | 689,569 8.160% | 0 (Unchanged) | Filing |
| 2023-06-12 4:01 pm Purchase | 2023-06-09 | 13D | Elicio Therapeutics, Inc. ELTX | Clal Biotechnology Industries Ltd. | 689,569 7.110% | 689,569 (New Position) | Filing |